Heartflow, Inc. (NASDAQ:HTFL – Get Free Report) insider Campbell Rogers sold 16,918 shares of the company’s stock in a transaction dated Thursday, March 19th. The shares were sold at an average price of $25.00, for a total value of $422,950.00. Following the completion of the sale, the insider owned 16,918 shares of the company’s stock, valued at $422,950. This represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Campbell Rogers also recently made the following trade(s):
- On Thursday, October 22nd, Campbell Rogers sold 12,157 shares of Heartflow stock. The stock was sold at an average price of $55.01, for a total transaction of $668,756.57.
- On Friday, September 18th, Campbell Rogers sold 12,156 shares of Heartflow stock. The stock was sold at an average price of $50.15, for a total transaction of $609,623.40.
- On Tuesday, November 17th, Campbell Rogers sold 12,157 shares of Heartflow stock. The stock was sold at an average price of $46.39, for a total value of $563,963.23.
- On Tuesday, November 17th, Campbell Rogers sold 24,188 shares of Heartflow stock. The shares were sold at an average price of $46.39, for a total value of $1,122,081.32.
- On Thursday, October 22nd, Campbell Rogers sold 23,933 shares of Heartflow stock. The stock was sold at an average price of $55.01, for a total transaction of $1,316,554.33.
- On Friday, September 18th, Campbell Rogers sold 19,682 shares of Heartflow stock. The stock was sold at an average price of $50.15, for a total value of $987,052.30.
Heartflow Stock Performance
NASDAQ:HTFL opened at $46.69 on Friday. Heartflow, Inc. has a 52-week low of $20.13 and a 52-week high of $60.65. The company has a market cap of $4.10 billion, a PE ratio of -50.75 and a beta of 2.50. The stock has a 50-day simple moving average of $51.76 and a 200 day simple moving average of $35.64.
Heartflow (NASDAQ:HTFL – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.15. Heartflow had a negative net margin of 33.11% and a negative return on equity of 20.53%. The business had revenue of $72.86 million during the quarter. During the same quarter in the previous year, the company posted ($0.27) EPS. On average, research analysts predict that Heartflow, Inc. will post -0.75 earnings per share for the current fiscal year.
Institutional Trading of Heartflow
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Algert Global LLC bought a new position in shares of Heartflow in the 3rd quarter worth about $2,960,000. Castleark Management LLC acquired a new position in Heartflow during the 3rd quarter valued at about $4,713,000. Virtu Financial LLC acquired a new position in Heartflow during the 3rd quarter valued at about $1,028,000. Allworth Financial LP grew its holdings in Heartflow by 56.5% during the third quarter. Allworth Financial LP now owns 828 shares of the company’s stock worth $41,000 after buying an additional 299 shares in the last quarter. Finally, Entropy Technologies LP raised its holdings in shares of Heartflow by 7.1% in the third quarter. Entropy Technologies LP now owns 10,156 shares of the company’s stock valued at $505,000 after purchasing an additional 672 shares during the last quarter.
Key Headlines Impacting Heartflow
Investors following HTFL have been watching these headlines:
- Positive Sentiment: A report headline says Heartflow’s Q2 revenue beat consensus and the company raised its full-year guidance—potentially signaling stronger growth expectations. The provided article text offers few details on the results. Article: HeartFlow Q2 revenue and guidance
- Negative Sentiment: Recent coverage flagged insider share sales, including a transaction reported at about $4.2 million. Other reports describe Campbell Rogers’ sales, some made under pre-arranged Rule 10b5-1 plans. Insider selling can unsettle investors, although planned sales do not necessarily signal a change in the insider’s view of the company. Article: Heartflow insider sale
- Negative Sentiment: Put-option trading rose sharply, with 6,628 puts traded—about 558% above the reported average. This may reflect increased demand for downside protection or bearish bets, though options activity alone does not establish investors’ outlook.
Wall Street Analyst Weigh In
A number of brokerages have weighed in on HTFL. Stifel Nicolaus boosted their price target on Heartflow from $45.00 to $70.00 and gave the stock a “buy” rating in a research report on Friday, November 13th. Benchmark restated a “buy” rating on shares of Heartflow in a research report on Friday, August 14th. Wells Fargo & Company raised their price objective on Heartflow from $39.00 to $70.00 and gave the stock an “overweight” rating in a research note on Friday, November 13th. UBS Group started coverage on Heartflow in a report on Wednesday, September 9th. They issued a “neutral” rating and a $55.00 price objective for the company. Finally, Canaccord Genuity Group upped their price objective on shares of Heartflow from $56.00 to $69.00 and gave the stock a “buy” rating in a research report on Friday, November 13th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $60.12.
Read Our Latest Stock Analysis on HTFL
Heartflow Company Profile
HeartFlow, Inc. is a medical technology company that develops noninvasive tools to help clinicians assess coronary artery disease. Its platform analyzes coronary CT angiography scans to create personalized models of a patient’s coronary arteries and provide information that can support diagnosis and treatment planning. The company’s offerings include HeartFlow FFR CT Analysis, which estimates blood flow and the effects of artery narrowing, and tools for assessing coronary plaque. The technology combines medical imaging with computational analysis and artificial intelligence, giving clinicians information without requiring an invasive procedure to measure blood flow.
Featured Stories
- Five stocks we like better than Heartflow
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Heartflow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heartflow and related companies with MarketBeat.com's FREE daily email newsletter.
